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Sustained Effects of Interleukin-1-Receptor Antagonist
Treatment in Type 2 Diabetes Mellitus
Abstract
Objective: Interleukin (IL)-1 impairs insulin secretion and induces beta-cell apoptosis. Pancreatic
beta-cell IL-1 expression is increased and interleukin-1-receptor antagonist (IL-1Ra) expression reduced
in patients with type 2 diabetes mellitus. Treatment with recombinant IL-1Ra improves glycemia and
beta-cell function and reduces inflammatory markers in patients with type 2 diabetes mellitus. Here we
investigated the durability of these responses. Research Design and Methods: Among 70 ambulatory
patients with type 2 diabetes and A1C and body mass index higher than 7.5% and 27, respectively,
randomly assigned to receive 13 weeks of anakinra, a recombinant human IL-1Ra, or placebo, 67
completed treatment and were included in this double-blinded 39 week follow-up study. Primary
outcome was change in betacell function following anakinra withdrawal. Analysis was done by
intention-to-treat. Results: Thirty-nine weeks following anakinra withdrawal the proinsulin to insulin
(PI/I) ratio but not stimulated C-peptide remained improved by -0.07 (95% CI -0.14 to -0.02, P=0.011)
compared to placebo treated patients. Interestingly, a subgroup characterized by genetically determined
low baseline IL-1Ra serum levels, maintained the improved stimulated C-peptide obtained by 13 weeks
of IL-1Ra treatment. Reductions of C-reactive protein (-3.2 mg/l [95% CI -6.2 to -1.1, P=0.014]) and of
IL-6 (-1.4 ng/l [95% CI -2.6 to -0.3, P=0.036]) were maintained until end of study. Conclusions: IL-1
blockade with anakinra induces improvement of the PI/I ratio and in markers of systemic inflammation
lasting 39 weeks following treatment withdrawal.
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Objective: Interleukin (IL)-1 impairs insulin secretion and induces beta-cell apoptosis. Pancreatic 
beta-cell IL-1 expression is increased and interleukin-1-receptor antagonist (IL-1Ra) expression 
reduced in patients with type 2 diabetes mellitus. Treatment with recombinant IL-1Ra improves 
glycemia and beta-cell function and reduces inflammatory markers in patients with type 2 
diabetes mellitus.  Here we investigated the durability of these responses. 
 
Research Design and Methods: Among 70 ambulatory patients with type 2 diabetes and A1C 
and body mass index higher than 7.5% and 27, respectively, randomly assigned to receive 13 
weeks of anakinra, a recombinant human IL-1Ra, or placebo, 67 completed treatment and were 
included in this double-blinded 39 week follow-up study. Primary outcome was change in beta-
cell function following anakinra withdrawal. Analysis was done by intention-to-treat.  
 
Results: Thirty-nine weeks following anakinra withdrawal the proinsulin to insulin (PI/I) ratio 
but not stimulated C-peptide remained improved by -0.07 (95% CI -0.14 to -0.02, P=0.011) 
compared to placebo treated patients. Interestingly, a subgroup characterized by genetically 
determined low baseline IL-1Ra serum levels, maintained the improved stimulated C-peptide 
obtained by 13 weeks of IL-1Ra treatment. Reductions of C-reactive protein (-3.2 mg/l [95% CI 
-6.2 to -1.1, P=0.014]) and of IL-6 (-1.4 ng/l [95% CI -2.6 to -0.3, P=0.036]) were maintained 
until end of study.  
 
Conclusions: IL-1 blockade with anakinra induces improvement of the PI/I ratio and in markers 
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ype 2 diabetes mellitus is 
caused by inability of the 
functional beta-cell mass to 
compensate for increased insulin needs due to 
insulin resistance (1). During the course of the 
disease beta-cell function progressively 
declines irrespective of treatment with 
glucose-lowering drugs (2-4). Beta-cell mass 
is reduced through apoptosis (5) and type 2 
diabetes is associated with a low-grade 
systemic inflammation  (6), but the 
mechanisms underlying beta-cell failure and 
destruction in type 2 diabetes remain elusive.  
In vitro, long-term exposure to high 
glucose and the peptide hormone leptin 
secreted by adipose tissue, induce beta-cell 
apoptosis and production of the 
proinflammatory cytokine interleukin (IL)-1 
in beta-cells and pancreatic islets, respectively 
(7,8).  IL-1 inhibits the function and induces 
apoptosis of beta-cells (9) and has been 
implicated as a mediator of the beta-cell 
destruction leading to type 1 diabetes mellitus 
(10). Exogenous addition of interleukin-1-
receptor antagonist (IL-1Ra), a naturally 
occurring competitive inhibitor of IL-1 
signaling protects the beta-cells from the 
deleterious effects of high glucose and leptin 
exposure  (7,8).   
Both beta-cell expression and serum 
levels of IL-1Ra are reduced in patients with 
type 2 diabetes (8,11). This inadequate IL-1 
antagonism seems to be a genetic trait, since 
genetic polymorphisms in the gene encoding 
IL-1Ra are associated with altered serum 
levels of IL-1Ra (12-15). 
We previously showed that 13 weeks 
of IL-1Ra treatment improved beta-cell 
function, reduced A1C and markers of 
systemic inflammation in patients with type 2 
diabetes (16). The aim of this 39-week 
follow-up study was to investigate the 
durability of these effects. 
 
RESEARCH DESIGN AND METHODS 
Study Design and Patients: This 
study was a 52-week investigator-initiated, 
placebo-controlled, double-blind, parallel 
group randomized proof of concept clinical 
trial conducted in Switzerland (University 
Hospital Zurich) and Denmark (Steno 
Diabetes Center) between January 2004 and 
March 2006. The protocol for the study was 
in accordance with the declaration of Helsinki 
and approved by the local ethical committees. 
Written informed consent was provided by all 
patients before entering the study. 
The study was designed a priori in 
two parts (figure 1). The first part was a 13-
week intervention study to test the efficacy 
and safety of recombinant human IL-1Ra 
(anakinra, [Kineret])  in patients with type 2 
diabetes, with metabolic control as primary 
outcome and beta-cell function, insulin 
sensitivity and inflammatory markers as 
secondary outcomes, as reported previously 
(16). The second part of the study reported 
here (Consort information in Online 
Appendix available at 
http://care.diabetesjournals.org) was a 39-
week follow-up study commencing at the 
time of withdrawal of study drug to test the 
durability of the intervention on beta-cell 
function, inflammatory markers, insulin-
requirement and insulin-sensitivity. In the 
follow-up study glucose-lowering therapy 
was intensified if indicated, and insulin 
treatment was initiated if A1C was higher 
than 8.0% or fasting plasma glucose exceeded 
8 mmol per liter. Other medications were 
added or increased in dose at the discretion of 
the investigator. The study was unblinded 
after the last patient’s final visit (week 52). 
Inclusion and exclusion criteria have 
been described previously (16). Inclusion 
criteria were: Age of 20 years or more, type 2 
diabetes according to criteria from the 
American Diabetes Association (17) for more 
than 3 months, BMI > 27 kg/m2, A1C > 7.5%, 
and no change in either type or doses of 
medications in 3 months preceding the study. 
T 
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Briefly, exclusion criteria were: 
Autoantibodies to GAD 65 or islet cell 
antibody 512, A1C > 12%, fasting c-peptide < 
400 pmol/liter, and current treatment with 
anti-inflammatory drugs (low-dose aspirin 
was allowed). 
Study outcomes: Primary outcome of 
the follow-up study was change between 
baseline and 52 weeks in beta-cell secretory 
function measured by the fasting ratio of 
proinsulin to insulin (PI/I) and the area under 
the concentration–time curve (AUC) for 
stimulated C-peptide during an oral glucose-
tolerance test, an intravenous stimulation test 
with glucose, glucagon and arginine and the 
two tests combined. Secondary outcomes 
included change between baseline and 52 
weeks in IL-6, C-reactive protein (CRP), 
insulin requirements, A1C and  the 
homeostasis model assessment insulin-
sensitivity index (HOMA-SI) (18). 
Furthermore IL-1Ra genotypes were 
determined. 
Study Procedures: In the follow-up 
study patients were seen at week 13 on the 
last day of anakinra or placebo treatment and 
at weeks 26, 39 and 52. A1C was measured at 
every visit and glucose-lowering therapy was 
intensified if indicated.  At baseline, and at 13 
and 52 weeks, beta-cell secretory function 
was assessed by the fasting PI/I ratio and by a 
2-hour oral glucose-tolerance test directly 
followed by a 12-minute intravenous glucose, 
glucagon and arginine stimulation test as 
described previously (16).  Physical 
examination, funduscopy, routine safety 
blood tests and analysis of urinary albumin 
excretion were performed at baseline and 
after 13 and 52 weeks. At baseline whole 
blood was sampled for DNA analysis of the 
IL-1Ra gene (IL-1RN). 
Laboratory values: C-peptide, insulin, 
and proinsulin were determined at the Steno 
Diabetes Center. Insulin and proinsulin were 
assessed by enzyme-linked immunosorbent 
assays, and C-peptide levels were determined 
by a time-resolved fluoroimmunoassay. IL-
1Ra, IL-6 and CRP were measured at the 
University Hospital Zurich by enzyme-linked 
immunosorbent assays. Measurements of 
A1C levels and routine clinical laboratory 
tests were performed locally in the central 
laboratory units of the two participating 
centers. DNA was extracted from whole 
blood buffy coats by the Maxwell® 16 
System (Promega). Genotyping the variable 
number tandem repeat (VNTR) 
polymorphism in intron 2 of IL-1RN was 
analyzed as described previously (19) with 
use of the (Forward) 5′-CTC AGC AAC ACT 
CCTAT-3′ and (Reverse) 5′-TCC TGG TCT 
GCA GGTAA-3′ primers and separation of 
the PCR products on 2% agarose gel. 
Genotyping of the single nucleotide 
polymorphism (SNP) tagged by rs4251961 
near 5’ of IL-1RN (13) was performed using 
TaqMan® SNP Genotyping Assays (c-
32060323-10, Applied Biosystems) according 
to the manufacturer's description.  
Statistical Analysis: All end points 
were analyzed in the intention-to-treat 
population, defined as patients completing 13 
week of anakinra or placebo treatment. 
Missing data were imputed by last 
observation carried forward. Differences in 
continuous variables were compared by two-
sample t-test. The Mann-Whitney test was 
used in the case of non-normal distribution. 
For categorical variables, Fisher’s Exact test 
was used. Correlations were analyzed by 
regression analysis. A P value of less than 




Thirty-three of 34, who finished 
anakinra treatment, and 31 of 33 patients, who 
finished placebo treatment, completed the 
study (figure 1).  
At the end of the study, 39 weeks 
following withdrawal of anakinra or placebo 
treatment, PI/I ratio was lower in the former 
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anakinra treated patients compared to the 
former placebo treated patients with a 
baseline adjusted between-group difference of 
-0.07 (95% CI  -0.14 to -0.02, P=0.011) 
(figure 2A). No differences in AUC for C-
peptide during the oral glucose-tolerance test, 
the intravenous stimulation test and the 
combined test at study end between former 
anakinra and placebo treated patients were 
observed with baseline adjusted between-
group differences of 11.0 nmol/liter x min 
(95% CI -13.4 to 35.3, P=0.224), 2.9 
nmol/liter x min (95% CI -3.1 to 9.0, 
P=0.333) and 11.1 nmol/liter x min (95% CI -
18.3 to 40.6, P=0.282) for the oral, 
intravenous and combined test, respectively.  
Following 39 weeks of anakinra 
withdrawal CRP (-3.2 mg/l [95% CI -6.2 to -
1.1, P=0.014]) (figure 2C) and IL-6 (-1.4 ng/l 
[95% CI -2.6 to -0.3, P=0.036]) (figure 2D) 
were reduced compared to placebo-group 
patients. No correlation between the reduction 
in PI/I ratio and the reductions in CRP 
(r2=0.007, P=0.670) or IL-6 (r2=0.012, 
P=0.556) was observed in the anakinra treated 
patients. 
At 52 weeks the baseline adjusted 
mean difference in A1C from baseline 
between the former anakinra and placebo 
treated patients was -0.05% (95% CI -0.62 – 
0.52, P=0.867) (figure 2B). The absolute 
mean reduction in A1C was from 8.7 (SE 0.2) 
% to 7.8 (0.2) % and from 8.2 (0.2) % to 7.4 
(0.1) % in the anakinra and placebo groups, 
respectively.  Insulin sensitivity at study end 
assessed by HOMA-SI was unchanged with a 
baseline adjusted between-group difference 
(anakinra vs. placebo) of -0.04 l2/mM x mU 
(95% CI -0.20 to 0.13, P=0.485). The average 
daily insulin dose from withdrawal of 
anakinra or placebo treatment until week 52 
increased by 18.9 (4.0) IU and 28.5 (7.9) IU 
(P=0.670) in the anakinra and placebo groups, 
respectively. Daily metformin dose was 
increased by 69 (50) mg and 308 (115) mg 
(P=0.257) in the anakinra and placebo groups, 
respectively. Other oral glucose lowering 
medications were unchanged during the 
study. 
Statins were initiated in 7 and 8 
patients during the follow-up of anakinra and 
placebo treated patients, respectively. Three 
anakinra and 4 placebo group patients started 
aspirin during the follow-up. The average 
weight gain during the study for anakinra and 
placebo treated patients was 1.3 (SE 0.6) kg 
and 1.7 (0.8) kg (P=0.678), respectively. 
Three symptomatic self-reported 
hypoglycemic episodes were noted; two in the 
placebo group and 1 in the anakinra treated 
group. No change in blood pressure, lipids, 
24-hour urinary albumin excretion, or retinal 
fundus photo was observed during the study. 
As reported previously (16) 21 of 34 
patients responded to treatment defined as any 
reduction in A1C following 13 weeks of 
anakinra treatment (responders to anakinra), 
whereas 10 of 33 patients on placebo 
treatment experienced  reductions in A1C 
(P<0.0001). To characterize the responders to 
anakinra treatment a subgroup analysis was 
performed. At baseline patients responding to 
anakinra (n=21) were older (P=0.015) and had 
a higher rate of cardiovascular disease 
(P=0.009) compared to non-responders to 
anakinra (n=13) (Online Appendix Table A1). 
Furthermore baseline IL-1Ra serum 
level was lower in responders compared to 
non-responders to anakinra (519 [SE 104] 
pg/liter vs 1299 [314] pg/liter, P=0.009) and 
remained unchanged at the end of the study 
(figure 3A). As polymorphisms of the IL1RN 
gene encoding IL-1Ra have been associated 
to serum levels of the protein, two IL1RN 
gene polymorphisms were investigated. Allele 
2 of the VNTR polymorphism in intron 2 of 
the gene has been associated with an 
increased serum IL-1Ra level (12,15). An 
overall correlation between allele 2 carrier 
status and baseline serum IL-1ra levels was 
found (r2=0.18, P=0.021); however, there was 
no difference between responders and non-
IL-1Ra and sustained beta-cell function 
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responders with respect to allele 2 frequency 
(P=1.0) (figure 3B). Allele C of the SNP 
rs4251961 tagging near 5’ of  IL1RN  has 
been associated with a lower serum IL-1Ra 
level and higher serum CRP and IL-6 levels 
(13,14). In this study the correlation between 
allele C carrier status and baseline serum IL-
1ra levels was confirmed (r2=0.46, P<0.001), 
however no correlation to baseline CRP 
(r2=0.11, P=0.124) or IL-6 (r2=0.06, P=0.254) 
was found. Allele C frequency was higher 
(58%) in the responders to anakinra treatment 
than in the non-responders (21%., P=0.007) 
(figure 3B).  
Identical target A1C at 52 weeks 
(figure 3C) was reached with lower increases 
in insulin dose (10.8 [SE 2.6] IU/day) in the 
patients responding to anakinra compared to 
anakinra unresponsive patients (31.4 [6.0] 
IU/day, P=0.006) (figure 3D). 
At the end of anakinra treatment 
(week 13) responders to anakinra showed 
improved beta-cell function as assessed by the 
PI/I ratio (P=0.041) and AUC for C-peptide 
during the stimulation tests (oral test: 
P=0.006, intravenous test: P=0.048, and 
combined tests: P=0.025) compared to 
patients not responding to anakinra treatment 
(figure 4). The improved beta-cell function in 
responders to anakinra treatment was 
maintained 39 weeks after anakinra 
withdrawal, whereas a reduction in beta-cell 
function in non-responders to anakinra 
treatment was seen 39 weeks after anakinra 
withdrawal (figure 4), with the exception of 
the AUC for C-peptide of the intravenous 
stimulation test, which was unchanged 
(P=0.793) (figure 4C). The inflammatory 
markers CRP and IL-6 were reduced 
compared to baseline both at the time of 
anakinra withdrawal and at the end of the 
study irrespectively of whether the patients 
were responsive (reduction in A1C) or 
unresponsive to anakinra treatment. No 
correlation between the changes in CRP and 
IL-6 and any measurement of beta-cell 
function in either of the two subgroups were 
found (data not shown).  No subgroup 
differences in insulin-sensitivity measured by 
HOMA-SI were observed. 
 
CONCLUSIONS 
In the first part of this clinical trial we 
reported that 13 weeks of IL-1Ra treatment 
with anakinra reduced A1C, improved beta-
cell function and reduced inflammatory 
markers (16). In the present protocolled 
follow-up study we show that the reduced PI/I 
ratio and the CRP and IL-6 serum levels were 
maintained 39 weeks after anakinra 
withdrawal, indicating that at least 39 weeks 
of remission of these parameters were caused 
by 13 weeks of anakinra treatment. 
Furthermore a subgroup analysis 
showed that the 21 (62%) patients, who 
experienced any reduction in A1C following 
13 weeks of IL-1Ra treatment with anakinra 
(responders), maintained their anakinra-
induced improved beta-cell function assessed 
by both the PI/I ratio and stimulatory testing 
39 weeks after anakinra withdrawal, whereas 
the beta-cell function of the patients treated 
with placebo and those unresponsive to 
anakinra treatment further deteriorated 
following cessation of placebo and anakinra 
therapy, respectively. The superior beta-cell 
function of the anakinra responsive patients 
was reflected by a lower insulin requirement 
to obtain target glycemia in this group.  
The preserved beta-cell function 39 
weeks following anakinra withdrawal 
indicates that modulation of beta-cell function 
or increased beta-cell mass occurred during 
IL-1Ra therapy. Apart from one study using 
short term  intensive insulin treatment (20) 
where the 45-51% who responded had 
maintained acute insulin response to 
intravenous glucose testing, no other therapy 
has been shown to maintain beta-cell function 
in type 2 diabetes following treatment 
withdrawal. 
IL-1Ra and sustained beta-cell function 
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Both leptin and hyperglycemia induce IL-1 
production in the pancreatic islets (7,8). 
Reduction of hyperglycemia improves beta-
cell function (20). However the improvement 
of beta-cell function observed in this study 
does not seem to be a consequence of 
improved glycemia per se since declining 
beta-cell function was observed in patients 
not responsive to anakinra and placebo group 
patients, irrespective of the improved 
glycemic control obtained during the follow-
up phase. This suggests that the inhibition of 
IL-1 signaling was the mechanism behind the 
improved beta-cell function.  
Elevated IL-1Ra serum levels are 
found in non-diabetic individuals prone to 
develop type 2 diabetes (21), whereas patients 
with overt type 2 diabetes have reduced beta-
cell expression and serum levels of IL-1Ra 
(8,11), indicating that a down-regulation of  
IL-1Ra expression is a consequence of the 
diabetic state. In this study low baseline IL-
1Ra serum levels predicted the glycemic and 
beta-cell secretory responses to anakinra 
treatment. The increased frequency of the C 
allele of SNP rs4251961, associated with 
lower IL-1Ra and higher IL-1 serum levels 
(13,14) in the responders to anakinra 
treatment indicates that the observed 62% 
response-rate to anakinra treatment may be 
genetically determined. In accordance with 
this notion we have previously shown that 
beta-cells from 6 out of 10  patients with type 
2 diabetes expressed IL-1 mRNA (22).  The 
observed frequencies of the T and C alleles of 
SNP rs4251961 in this study did not differ 
from the frequencies in populations without 
type 2 diabetes (13,14), indicating that the C 
allele is not predisposing to diabetes 
development per se, but is a pharmaco-
genetic bio-marker for a glycemic response to 
anakinra treatment. 
The lack of association between 
changes in CRP and IL-6, surrogate markers 
of systemic IL-1 activity, and the PI/I ratio or 
any reduction in A1C following anakinra 
therapy indicates that systemic inflammation 
is not likely to affect beta-cell function, and 
that the improved beta-cell function caused by 
anakinra treatment is due to inhibition of IL-1 
produced in the vicinity of the beta-cell. IL-1 
production could thus originate from the beta-
cell (7) or from macrophages infiltrating the 
islets (23) as the IL-1B gene is overexpressed 
in blood monocytes from patients with type 2 
diabetes (24). 
The sustained reduction of CRP and 
IL-6 levels at 39 weeks after anakinra 
withdrawal is notable, and indicates that 
transient IL-1 blockade is capable of inducing 
not only a metabolic but also a 39- week long 
inflammatory remission. In this study the 
inflammatory remission was not related to 
insulin sensitivity. This is in line with recent 
findings from the Whitehall II study (25).  
Limitations to this follow-up study 
include that multiple hypotheses were tested 
and that a subgroup analysis was performed.    
In summary, this study suggests that 
13 weeks of anakinra treatment is capable of 
inducing a 39-week long preservation of beta-
cell function and a similar inflammatory 
remission in patients with type 2 diabetes. 
Low baseline serum IL-1Ra levels predicted 
the metabolic response, and this phenotypic 
trait was associated with the C-allele of an IL-
1RN SNP. Future studies will have to confirm 
these results and to test higher doses and 
longer treatment and follow-up periods in 
patients with type 2 diabetes selected based 
on their IL-1RN SNP genotype. If confirmed 
the perspective of these findings is that 
anakinra treatment could be used as 
substitution therapy in patients with type 2 
diabetes with genetically determined IL-1Ra 
deficiency and as induction therapy during 
flares of hyperglycemia during the course of 
the disease.  
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Fig. 1: Enrollment and outcome. 
Of the 70 patients who underwent randomization, 67 completed 13 weeks of anakinra or placebo 
treatment and were included in the present 39 week follow-up study. Thirty-three and 31 of the 
former anakinra and placebo treated patients, respectively, completed the study. 
 
Fig. 2: Change in glycemic and inflammatory markers at study end. 
Data of proinsulin to insulin ratio (A), A1C (B), C-reactive protein (C) and interleukin-6 at 
baseline and end of study (week 52) in patients treated with anakinra (former anakinra = black 
bars) or placebo (former placebo = white bars) from baseline until week 13. Data are mean (SE). 
 
Fig. 3: Interleukin-1-receptor-antagonist serum levels and genotypes, and A1C and insulin 
requirements.  
(A) Serum interleukin-1-receptor antagonist levels at baseline and end of study (week 52) in 
patients with (responders = white bars)) or without (non-responders = black bars) any reduction 
in A1C following 13 weeks of anakinra treatment. (B) Allele frequencies of allele 2 and C of the 
VNTR tandem repeat polymorphism in intron 2 and the SNP tagged by rs4251961, respectively, 
of the interleukin-1-recpetor antagonist gene in responders (white bars) and non-responders 
(black bars) to anakinra treatment. (C) A1C at baseline (week 0), and 13, 26, 39 and 52 weeks in 
responders (white squares) and non-responders (black triangles) to anakinra treatment. (D) Daily 
insulin dose at baseline and end of study (week 52) in responders and non-responders to anakinra 
treatment. Data are mean (SE) or frequencies where indicated. 
 
Fig. 4: Beta-cell function following anakinra withdrawal. 
Beta-cell function assessed by the ratio of proinsulin to insulin (A), and AUC for C-peptide 
during an oral glucose-tolerance test (B), an intravenous stimulation with glucose, glucagon and 
arginine (C) and the oral and intravenous test combined (D) at baseline, anakinra withdrawal 
(week 13) and end of study (week 52) in patients with (responders = white bars) or without (non-
responders = black bars) any reduction in A1c following 13 weeks of anakinra treatment. (A) 
*P=0.041 vs non-responders at week 13, †P=0.435 vs responders week 52, ‡P=0.016 vs non-
responders week 52 and §P=0.005 vs non-responders week 52.  (B) *P=0.006 vs non-responders 
at week 13, †P=0.750 vs responders week 52, ‡P=0.021 vs non-responders week 52 and 
§P=0.008 vs non-responders week 52. (C) *P=0.048 vs non-responders at week 13, †P=0.039 vs 
responders week 52, ‡P=0.793 vs non-responders week 52 and §P=0.092 vs non-responders 
week 52. (D) *P=0.025 vs non-responders at week 13, †P=0.947 vs responders week 52, 
‡P=0.021 vs non-responders week 52 and §P=0.001 vs non-responders week 52. Data are mean 
(SE). 
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